BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 26902
Title: FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Reviewer's code: 02543925
Reviewer's country: United States
Science editor: Jing Yu
Date sent for review: 2016-05-02 16:09
Date reviewed: 2016-05-12 05:42

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[Y] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[Y] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

This review article summarizes current chemotherapeutic treatment for pancreatic cancer, especially concerning predictive factors for clinical responses. It also provides perspectives for personalized chemotherapy for this cancer with extremely poor prognosis.

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 26902
Title: FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Reviewer's code: 03472766
Reviewer's country: Spain
Science editor: Jing Yu
Date sent for review: 2016-05-02 16:09
Date reviewed: 2016-05-15 21:57

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[Y] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[Y] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Overall, the authors nicely discuss the topic specific to the FOLFIRINOX treatment of patients with Pancreatic cancer. The presented review is easy to read, updated and well balanced. Thus I think only some minor revisions are required. The authors should mention and comment some important discoveries: 1. Mayers JR et al (Nature medicine 2014) have identified a pre-diagnostic signature of branched-chain amino acids (BCAAs) that could improve risk prediction up to five years before the disease appears. 2. Some other combinations, such as gemcitabine with gamma-secretase inhibitor (MK-0752) or connective tissue growth factor inhibitor (FG-3019) have also shown encouraging results. 3. A recent phase I study provided preliminary evidence of activity of gemcitabine combined with CP 870893 (a CD40 agonist) in chemotherapy-na?ve patients with advanced-stage PDAC (Beatty GL et al Clinical cancer research 2013) 4. In 2008 the allogenic cancer vaccine GVAX pancreas was developed, which is currently in phase II of clinical trial and is giving encouraging results (Laheru D et al. Clinical cancer research 2008) 5. Nywening TM et al have found that CCR2-targeted therapy with PF-04136309 in combination with FOLFIRINOX is safe and tolerable

(Lancet Oncology 2016)

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 26902
Title: FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Reviewer's code: 02510721
Reviewer's country: Italy
Science editor: Jing Yu
Date sent for review: 2016-05-02 16:09
Date reviewed: 2016-05-17 17:04

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[Y] Accept
[ ] Grade B: Very good	[ ] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The paper is a wide tuning of the complex topic of adjuvant therapy of pancreatic cancer. They are not highlited the difficulty of obtaining fragments of the neoplastic tissue and the stratification of patients according to the stage of evolution. The overall impression is that of a therapeutic theme evolving and far from widespread clinical application.